Tech Company Financing Transactions
Ikena Oncology Funding Round
Omega Funds, Atlas Venture and Bristol-Myers Squibb joined a $120 million Series B capital raise for Ikena Oncology. The round was announced on 1/6/2021.
Transaction Overview
Company Name
Announced On
1/6/2021
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Series B
Investors
Proceeds Purpose
Ikena intends to use the proceeds from this financing to advance its pipeline of targeted oncology therapies, including its novel development candidate TEAD inhibitor IK-930, and a new first-in-class preclinical program targeting KRAS signaling.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
50 Northern Ave. 7th Floor
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Website
Email Address
Overview
Ikena envisions a world where every cancer patient has a cure. Ikena, headquartered in the biotech hub of Boston, Massachusetts, is dedicated to bringing next generation targeted oncology and immunometabolism therapies to patients suffering from cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Manfredi
Chief Financial Officer
Douglas Carlson
Chief Medical Officer
Sergio Santillana
Chief Scientific Officer
Jeffrey Ecsedy
Vice President
Alfredo Castro
Vice President
Alexander Constan
Vice President
Karen McGovern
VP - Bus. Development
Maude Tessier
VP - Manufacturing
James Nolan
VP - R & D
Michelle Zhang
Browse more venture capital transactions:
Prev: 1/6/2021: BayoTech venture capital transaction
Next: 1/6/2021: Terns Pharmaceuticals venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs